CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 4 enrolled
Drug / intervention
migalastat HCldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00283959
NCT00283959Phase 2Completed
CompareCT.gov

A Phase 2, Open-Label, Single Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients With Fabry Disease

Amicus Therapeutics·interventional·Posted Jan 31, 2006·Updated Oct 31, 2018

In Brief

A Phase 2 clinical trial evaluating migalastat HCl for Fabry Disease. Completed, enrolled 4 participants across 2 sites in 2 countries.

Detailed Summary

Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) and how migalastat works in participants with Fabry disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFabry Disease
CountriesAustralia, Brazil
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 31, 2006
Enrollment StartJun 27, 2006
Primary CompletionMay 8, 2008
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.4 years ago

Interventions

migalastat HCldrug